Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Purpura, Thrombocytopenic, Idiopathic | 25 | 2024 | 233 | 13.130 |
Why?
|
Thrombocytopenia | 29 | 2024 | 1179 | 11.150 |
Why?
|
Telangiectasia, Hereditary Hemorrhagic | 19 | 2023 | 139 | 10.900 |
Why?
|
Anemia, Hemolytic, Congenital Nonspherocytic | 14 | 2024 | 51 | 7.860 |
Why?
|
Pyruvate Metabolism, Inborn Errors | 13 | 2024 | 45 | 6.630 |
Why?
|
Receptors, Thrombopoietin | 18 | 2024 | 157 | 6.330 |
Why?
|
Thrombopoietin | 19 | 2024 | 225 | 5.650 |
Why?
|
Pyruvate Kinase | 15 | 2024 | 189 | 4.650 |
Why?
|
Receptors, Fc | 17 | 2024 | 541 | 4.230 |
Why?
|
Recombinant Fusion Proteins | 19 | 2024 | 3772 | 3.310 |
Why?
|
Benzoates | 11 | 2024 | 217 | 3.290 |
Why?
|
Hydrazines | 9 | 2024 | 226 | 2.900 |
Why?
|
Venous Thromboembolism | 14 | 2023 | 1671 | 2.700 |
Why?
|
Thrombosis | 13 | 2023 | 2968 | 2.600 |
Why?
|
Hemorrhage | 15 | 2023 | 3461 | 2.500 |
Why?
|
Thiophenes | 8 | 2023 | 588 | 2.400 |
Why?
|
Anemia | 7 | 2022 | 1506 | 2.200 |
Why?
|
Anticoagulants | 17 | 2023 | 4599 | 1.960 |
Why?
|
Hematologic Agents | 3 | 2018 | 39 | 1.910 |
Why?
|
Pyrazoles | 9 | 2024 | 1972 | 1.900 |
Why?
|
Hemophilia A | 3 | 2022 | 351 | 1.890 |
Why?
|
Blood Coagulation | 5 | 2020 | 1127 | 1.650 |
Why?
|
Angiodysplasia | 2 | 2021 | 23 | 1.600 |
Why?
|
Quinolines | 5 | 2024 | 732 | 1.580 |
Why?
|
Thiazoles | 8 | 2023 | 1483 | 1.570 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2020 | 260 | 1.540 |
Why?
|
Blood Platelet Disorders | 2 | 2021 | 58 | 1.420 |
Why?
|
Hematologic Neoplasms | 4 | 2022 | 1832 | 1.390 |
Why?
|
Epistaxis | 8 | 2023 | 111 | 1.380 |
Why?
|
Anemia, Aplastic | 2 | 2022 | 226 | 1.370 |
Why?
|
Antineoplastic Agents | 11 | 2023 | 13695 | 1.300 |
Why?
|
Neoplasms | 12 | 2023 | 21683 | 1.150 |
Why?
|
Platelet Count | 9 | 2023 | 781 | 1.130 |
Why?
|
End Stage Liver Disease | 2 | 2021 | 314 | 1.100 |
Why?
|
Piperazines | 5 | 2024 | 2488 | 1.080 |
Why?
|
Venous Thrombosis | 4 | 2023 | 1239 | 1.050 |
Why?
|
Thrombophilia | 5 | 2021 | 305 | 1.000 |
Why?
|
Liver Diseases | 4 | 2021 | 1253 | 0.980 |
Why?
|
Hematologic Diseases | 3 | 2024 | 498 | 0.980 |
Why?
|
Humans | 129 | 2024 | 744343 | 0.920 |
Why?
|
Tranexamic Acid | 3 | 2021 | 146 | 0.910 |
Why?
|
von Willebrand Diseases | 2 | 2022 | 127 | 0.900 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2021 | 8 | 0.830 |
Why?
|
Hemophilia B | 1 | 2022 | 81 | 0.800 |
Why?
|
Factor VIIa | 1 | 2022 | 101 | 0.790 |
Why?
|
Thrombocytosis | 1 | 2021 | 81 | 0.760 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2022 | 183 | 0.760 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2021 | 293 | 0.750 |
Why?
|
Doxycycline | 1 | 2022 | 326 | 0.740 |
Why?
|
Anemia, Hemolytic | 1 | 2021 | 168 | 0.740 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 2020 | 131 | 0.730 |
Why?
|
Antiphospholipid Syndrome | 1 | 2021 | 173 | 0.710 |
Why?
|
Hexokinase | 1 | 2020 | 125 | 0.710 |
Why?
|
Cyclosporine | 1 | 2022 | 786 | 0.690 |
Why?
|
Intergenerational Relations | 1 | 2019 | 68 | 0.690 |
Why?
|
Atrial Appendage | 1 | 2023 | 283 | 0.690 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 1965 | 0.690 |
Why?
|
Hemoglobins | 6 | 2022 | 1534 | 0.690 |
Why?
|
Porphyria, Acute Intermittent | 1 | 2019 | 15 | 0.680 |
Why?
|
Liver Transplantation | 2 | 2021 | 2119 | 0.670 |
Why?
|
Hematology | 1 | 2022 | 221 | 0.670 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2019 | 424 | 0.640 |
Why?
|
Antibodies, Bispecific | 1 | 2020 | 164 | 0.640 |
Why?
|
Perforin | 1 | 2018 | 168 | 0.630 |
Why?
|
Autoantibodies | 5 | 2023 | 2035 | 0.630 |
Why?
|
Blood Coagulation Disorders | 1 | 2021 | 337 | 0.610 |
Why?
|
Hemoptysis | 1 | 2019 | 155 | 0.610 |
Why?
|
Plasma | 1 | 2020 | 575 | 0.580 |
Why?
|
Standard of Care | 1 | 2021 | 564 | 0.580 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 131 | 0.580 |
Why?
|
Erythrocytes | 3 | 2022 | 2455 | 0.580 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2021 | 365 | 0.570 |
Why?
|
Neutropenia | 1 | 2022 | 895 | 0.570 |
Why?
|
Vascular Malformations | 1 | 2022 | 454 | 0.560 |
Why?
|
Drug Hypersensitivity | 2 | 2022 | 884 | 0.560 |
Why?
|
Phenylthiohydantoin | 1 | 2017 | 193 | 0.550 |
Why?
|
Bacterial Vaccines | 1 | 2018 | 403 | 0.550 |
Why?
|
Truth Disclosure | 1 | 2019 | 436 | 0.530 |
Why?
|
Anaphylaxis | 1 | 2022 | 746 | 0.520 |
Why?
|
Blood Platelets | 3 | 2023 | 2508 | 0.520 |
Why?
|
Gastrointestinal Hemorrhage | 5 | 2022 | 1130 | 0.510 |
Why?
|
Bacteremia | 1 | 2021 | 962 | 0.500 |
Why?
|
Adult | 35 | 2024 | 214055 | 0.490 |
Why?
|
Fibrin Fibrinogen Degradation Products | 3 | 2021 | 426 | 0.480 |
Why?
|
Disclosure | 1 | 2020 | 736 | 0.470 |
Why?
|
Perioperative Care | 2 | 2018 | 1002 | 0.470 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2022 | 3508 | 0.470 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 895 | 0.470 |
Why?
|
Angiogenesis Inhibitors | 5 | 2022 | 2038 | 0.450 |
Why?
|
Antifibrinolytic Agents | 3 | 2021 | 254 | 0.450 |
Why?
|
alpha-Thalassemia | 2 | 2024 | 46 | 0.450 |
Why?
|
Viral Vaccines | 1 | 2018 | 636 | 0.440 |
Why?
|
Prognosis | 8 | 2023 | 29063 | 0.420 |
Why?
|
Virus Diseases | 1 | 2018 | 711 | 0.420 |
Why?
|
Female | 44 | 2023 | 380194 | 0.420 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9274 | 0.420 |
Why?
|
Recombinant Proteins | 1 | 2022 | 6622 | 0.410 |
Why?
|
Quality of Life | 8 | 2024 | 12804 | 0.410 |
Why?
|
Communication | 2 | 2022 | 3749 | 0.390 |
Why?
|
beta-Thalassemia | 2 | 2024 | 225 | 0.380 |
Why?
|
Treatment Outcome | 17 | 2023 | 63114 | 0.380 |
Why?
|
Pulmonary Embolism | 2 | 2020 | 2376 | 0.380 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 1978 | 0.370 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1354 | 0.360 |
Why?
|
Cystic Fibrosis | 1 | 2019 | 1177 | 0.360 |
Why?
|
Bacterial Infections | 1 | 2018 | 1401 | 0.360 |
Why?
|
Middle Aged | 28 | 2023 | 213383 | 0.350 |
Why?
|
Breast Neoplasms | 3 | 2022 | 20822 | 0.350 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 7279 | 0.350 |
Why?
|
Retrospective Studies | 17 | 2023 | 77449 | 0.340 |
Why?
|
Heparin, Low-Molecular-Weight | 3 | 2020 | 339 | 0.340 |
Why?
|
Fibrinolytic Agents | 3 | 2023 | 2158 | 0.330 |
Why?
|
Aminopyridines | 2 | 2022 | 542 | 0.330 |
Why?
|
Erythrocyte Transfusion | 4 | 2024 | 565 | 0.330 |
Why?
|
Pierre Robin Syndrome | 1 | 2010 | 113 | 0.320 |
Why?
|
Osteogenesis, Distraction | 1 | 2010 | 219 | 0.310 |
Why?
|
Male | 34 | 2023 | 350118 | 0.310 |
Why?
|
Peptide Fragments | 1 | 2020 | 5097 | 0.310 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6489 | 0.310 |
Why?
|
Prostate-Specific Antigen | 1 | 2017 | 2494 | 0.310 |
Why?
|
Recurrence | 5 | 2019 | 8340 | 0.300 |
Why?
|
Platelet Aggregation | 2 | 2021 | 798 | 0.290 |
Why?
|
Critical Illness | 5 | 2021 | 2670 | 0.270 |
Why?
|
Mandible | 1 | 2010 | 740 | 0.270 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2023 | 3068 | 0.260 |
Why?
|
Aged | 18 | 2022 | 163280 | 0.250 |
Why?
|
Double-Blind Method | 4 | 2023 | 12026 | 0.250 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13102 | 0.250 |
Why?
|
Atrial Fibrillation | 1 | 2023 | 5034 | 0.250 |
Why?
|
Iron | 2 | 2022 | 1774 | 0.240 |
Why?
|
Disease Susceptibility | 3 | 2019 | 1782 | 0.230 |
Why?
|
Complement Inactivating Agents | 1 | 2023 | 50 | 0.230 |
Why?
|
Platelet Factor 4 | 1 | 2023 | 129 | 0.230 |
Why?
|
Arteriovenous Malformations | 3 | 2023 | 396 | 0.220 |
Why?
|
Erythrocytes, Abnormal | 1 | 2023 | 125 | 0.220 |
Why?
|
Administration, Oral | 3 | 2020 | 3913 | 0.220 |
Why?
|
Purpura, Thrombocytopenic | 1 | 2022 | 43 | 0.220 |
Why?
|
Splanchnic Circulation | 1 | 2022 | 110 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
Iron Overload | 1 | 2024 | 242 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2018 | 10943 | 0.200 |
Why?
|
Iron Chelating Agents | 1 | 2022 | 139 | 0.200 |
Why?
|
Child | 8 | 2022 | 77709 | 0.200 |
Why?
|
Disease Management | 3 | 2021 | 2459 | 0.190 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2021 | 93 | 0.190 |
Why?
|
Stroke | 1 | 2023 | 9981 | 0.190 |
Why?
|
Bone Density | 2 | 2024 | 3468 | 0.180 |
Why?
|
Bone Marrow Diseases | 1 | 2022 | 231 | 0.180 |
Why?
|
Prothrombin | 1 | 2020 | 185 | 0.180 |
Why?
|
Weight Gain | 1 | 2010 | 2292 | 0.180 |
Why?
|
Paternalism | 1 | 2019 | 46 | 0.180 |
Why?
|
Hemolysis | 1 | 2022 | 420 | 0.180 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2021 | 142 | 0.180 |
Why?
|
Indazoles | 1 | 2021 | 289 | 0.180 |
Why?
|
Portal Vein | 1 | 2022 | 437 | 0.180 |
Why?
|
Menorrhagia | 1 | 2019 | 63 | 0.170 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 141 | 0.170 |
Why?
|
Young Adult | 8 | 2021 | 56430 | 0.170 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 538 | 0.170 |
Why?
|
Ristocetin | 1 | 2018 | 26 | 0.170 |
Why?
|
Intensive Care Units | 3 | 2021 | 3679 | 0.170 |
Why?
|
Aged, 80 and over | 8 | 2022 | 57776 | 0.170 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 648 | 0.170 |
Why?
|
Hyperammonemia | 1 | 2020 | 76 | 0.170 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15519 | 0.170 |
Why?
|
Premedication | 1 | 2019 | 258 | 0.170 |
Why?
|
Normal Distribution | 1 | 2019 | 280 | 0.170 |
Why?
|
Blood Coagulation Tests | 1 | 2019 | 263 | 0.160 |
Why?
|
Blood Loss, Surgical | 2 | 2019 | 662 | 0.160 |
Why?
|
Bilirubin | 1 | 2020 | 425 | 0.160 |
Why?
|
Platelet Transfusion | 2 | 2018 | 314 | 0.160 |
Why?
|
ABO Blood-Group System | 1 | 2020 | 367 | 0.160 |
Why?
|
Adenosine Diphosphate | 1 | 2018 | 425 | 0.150 |
Why?
|
Patient Discharge | 1 | 2010 | 3313 | 0.150 |
Why?
|
Plasma Exchange | 1 | 2018 | 152 | 0.150 |
Why?
|
von Willebrand Factor | 1 | 2021 | 669 | 0.150 |
Why?
|
Reference Standards | 1 | 2021 | 1025 | 0.150 |
Why?
|
Arachidonic Acid | 1 | 2018 | 434 | 0.150 |
Why?
|
Perioperative Period | 1 | 2018 | 256 | 0.150 |
Why?
|
Length of Stay | 1 | 2010 | 6309 | 0.150 |
Why?
|
Benzimidazoles | 1 | 2022 | 850 | 0.150 |
Why?
|
Risk Assessment | 5 | 2023 | 23338 | 0.140 |
Why?
|
Risk Factors | 8 | 2023 | 72290 | 0.140 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4149 | 0.140 |
Why?
|
Postpartum Hemorrhage | 1 | 2019 | 258 | 0.140 |
Why?
|
Genes, Dominant | 1 | 2019 | 880 | 0.140 |
Why?
|
Syndrome | 1 | 2022 | 3251 | 0.130 |
Why?
|
Heart Failure | 1 | 2019 | 10900 | 0.130 |
Why?
|
Salvage Therapy | 1 | 2022 | 1275 | 0.130 |
Why?
|
Craniosynostoses | 1 | 2020 | 401 | 0.130 |
Why?
|
Rabbits | 1 | 2022 | 4894 | 0.130 |
Why?
|
Advisory Committees | 1 | 2019 | 775 | 0.130 |
Why?
|
Antithrombins | 1 | 2018 | 304 | 0.130 |
Why?
|
Epinephrine | 1 | 2018 | 792 | 0.130 |
Why?
|
Pyridones | 1 | 2020 | 712 | 0.130 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 664 | 0.130 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1261 | 0.130 |
Why?
|
Critical Pathways | 1 | 2019 | 476 | 0.130 |
Why?
|
Blood Transfusion | 1 | 2021 | 1301 | 0.130 |
Why?
|
Fatigue | 1 | 2022 | 1531 | 0.120 |
Why?
|
Siblings | 1 | 2019 | 854 | 0.120 |
Why?
|
Inpatients | 2 | 2023 | 2518 | 0.120 |
Why?
|
Living Donors | 1 | 2019 | 620 | 0.120 |
Why?
|
Risk | 2 | 2023 | 9687 | 0.120 |
Why?
|
Drug Interactions | 1 | 2018 | 1460 | 0.120 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 1791 | 0.120 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2274 | 0.110 |
Why?
|
Chronic Disease | 2 | 2018 | 9146 | 0.110 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 8642 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2019 | 956 | 0.110 |
Why?
|
Hospitalization | 3 | 2022 | 10262 | 0.110 |
Why?
|
ROC Curve | 1 | 2020 | 3527 | 0.110 |
Why?
|
Paralysis, Obstetric | 1 | 2012 | 12 | 0.110 |
Why?
|
Nitriles | 1 | 2017 | 956 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1660 | 0.110 |
Why?
|
Aortic Valve | 1 | 2022 | 1922 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.100 |
Why?
|
Liver Cirrhosis | 1 | 2022 | 1863 | 0.100 |
Why?
|
Benzamides | 1 | 2017 | 1379 | 0.100 |
Why?
|
Autoimmunity | 1 | 2019 | 1349 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1938 | 0.100 |
Why?
|
Forecasting | 1 | 2021 | 2951 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3206 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2021 | 1580 | 0.100 |
Why?
|
Alleles | 2 | 2021 | 6933 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1972 | 0.100 |
Why?
|
Pyridines | 1 | 2022 | 2825 | 0.100 |
Why?
|
Brachial Plexus Neuropathies | 1 | 2012 | 122 | 0.090 |
Why?
|
Neovascularization, Pathologic | 1 | 2021 | 2635 | 0.090 |
Why?
|
Attention | 1 | 2021 | 2400 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4933 | 0.090 |
Why?
|
Veterans | 1 | 2023 | 2519 | 0.090 |
Why?
|
Collagen | 1 | 2018 | 2689 | 0.090 |
Why?
|
Aspartate Aminotransferases | 2 | 2022 | 418 | 0.090 |
Why?
|
Prevalence | 3 | 2021 | 15226 | 0.090 |
Why?
|
Adolescent | 4 | 2022 | 85781 | 0.090 |
Why?
|
Infant, Newborn | 3 | 2023 | 25625 | 0.090 |
Why?
|
Thrombolytic Therapy | 1 | 2018 | 2161 | 0.090 |
Why?
|
Patient Compliance | 1 | 2020 | 2684 | 0.090 |
Why?
|
Pyrimidines | 1 | 2021 | 2942 | 0.080 |
Why?
|
Alanine Transaminase | 2 | 2022 | 592 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14722 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2265 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3523 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 7913 | 0.080 |
Why?
|
Prospective Studies | 2 | 2022 | 53288 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2019 | 2400 | 0.070 |
Why?
|
Survival Rate | 1 | 2021 | 12788 | 0.070 |
Why?
|
United States | 5 | 2022 | 69872 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5535 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 8949 | 0.070 |
Why?
|
Genetic Testing | 1 | 2019 | 3444 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15540 | 0.070 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3843 | 0.070 |
Why?
|
Mutation | 5 | 2023 | 29786 | 0.070 |
Why?
|
Animals | 4 | 2022 | 168757 | 0.060 |
Why?
|
Terminology as Topic | 1 | 2012 | 1547 | 0.060 |
Why?
|
Enteral Nutrition | 1 | 2010 | 763 | 0.060 |
Why?
|
Rats | 1 | 2021 | 24260 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8388 | 0.060 |
Why?
|
Logistic Models | 1 | 2018 | 13408 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7181 | 0.060 |
Why?
|
Activin Receptors, Type II | 1 | 2023 | 127 | 0.050 |
Why?
|
Pregnancy | 2 | 2022 | 29144 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15076 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25043 | 0.050 |
Why?
|
Cell Shape | 1 | 2023 | 375 | 0.050 |
Why?
|
Infant | 2 | 2020 | 35136 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11524 | 0.050 |
Why?
|
Hemostasis | 1 | 2023 | 458 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39050 | 0.050 |
Why?
|
Splenectomy | 1 | 2022 | 395 | 0.050 |
Why?
|
Erythropoiesis | 1 | 2024 | 705 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17446 | 0.040 |
Why?
|
Cranial Sutures | 1 | 2020 | 93 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 343 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13881 | 0.040 |
Why?
|
Ammonia | 1 | 2020 | 239 | 0.040 |
Why?
|
Cohort Studies | 4 | 2022 | 40561 | 0.040 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2023 | 838 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 2018 | 128 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 881 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 40075 | 0.040 |
Why?
|
Sutures | 1 | 2020 | 299 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 41006 | 0.040 |
Why?
|
Alkaline Phosphatase | 1 | 2020 | 865 | 0.040 |
Why?
|
Genotype | 2 | 2021 | 12951 | 0.040 |
Why?
|
Heparin | 1 | 2023 | 1637 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15295 | 0.030 |
Why?
|
Genetic Diseases, Inborn | 1 | 2020 | 587 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2460 | 0.030 |
Why?
|
Triglycerides | 1 | 2022 | 2454 | 0.030 |
Why?
|
Vitamins | 1 | 2022 | 1622 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1071 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1855 | 0.030 |
Why?
|
Warfarin | 1 | 2020 | 1496 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3584 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 2987 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2864 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3952 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4560 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2020 | 2002 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2703 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9313 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2021 | 5317 | 0.020 |
Why?
|
Echocardiography | 1 | 2020 | 5102 | 0.020 |
Why?
|
Canada | 1 | 2012 | 2065 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3610 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10388 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6544 | 0.020 |
Why?
|
Neurosurgery | 1 | 2012 | 643 | 0.020 |
Why?
|
International Cooperation | 1 | 2012 | 1420 | 0.020 |
Why?
|
Europe | 1 | 2012 | 3339 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 19905 | 0.020 |
Why?
|
Liver | 1 | 2020 | 7474 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.010 |
Why?
|
Consensus | 1 | 2012 | 2959 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16365 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23403 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20129 | 0.010 |
Why?
|